Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro

IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the coronavirus disease 2019 (COVID-19) pandemic, continues to pose global health challenges despite the availability of approved vaccines and antiviral drugs. The emergence of new variants of SARS-CoV...

Full description

Saved in:
Bibliographic Details
Main Authors: Igor Andrade Santos, Victoria Riquena Grosche, Natasha Marques Cassani, Rodrigo Cássio Sola Veneziani, Gustavo Lima Ribeiro, Jairo Kenupp Bastos, Nilson Nicolau-Junior, Andres Merits, Carlos Henrique Gomes Martins, Mark Harris, Ana Carolina Gomes Jardim
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2025.1540934/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850144679452999680
author Igor Andrade Santos
Igor Andrade Santos
Victoria Riquena Grosche
Victoria Riquena Grosche
Victoria Riquena Grosche
Natasha Marques Cassani
Natasha Marques Cassani
Rodrigo Cássio Sola Veneziani
Gustavo Lima Ribeiro
Jairo Kenupp Bastos
Nilson Nicolau-Junior
Andres Merits
Carlos Henrique Gomes Martins
Mark Harris
Ana Carolina Gomes Jardim
Ana Carolina Gomes Jardim
author_facet Igor Andrade Santos
Igor Andrade Santos
Victoria Riquena Grosche
Victoria Riquena Grosche
Victoria Riquena Grosche
Natasha Marques Cassani
Natasha Marques Cassani
Rodrigo Cássio Sola Veneziani
Gustavo Lima Ribeiro
Jairo Kenupp Bastos
Nilson Nicolau-Junior
Andres Merits
Carlos Henrique Gomes Martins
Mark Harris
Ana Carolina Gomes Jardim
Ana Carolina Gomes Jardim
author_sort Igor Andrade Santos
collection DOAJ
description IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the coronavirus disease 2019 (COVID-19) pandemic, continues to pose global health challenges despite the availability of approved vaccines and antiviral drugs. The emergence of new variants of SARS-CoV-2 and ongoing post-COVID complications necessitate continuous exploration of effective treatments. Kaurenoic acid (KA) is a tetracyclic diterpenoid isolated from plants of the Copaifera genus and has been previously recognized for its anti-inflammatory, antibacterial, antifungal, and antitumor properties. However, there is a lack of knowledge about the in vitro effects of KA on viruses. Here, we evaluated its effect on SARS-CoV-2 replication for the first time.Methods and ResultsKA demonstrated a high selective index of 16.1 against SARS-CoV-2 and robust effectiveness against the B.1.617.2 (Delta) and BA.2 (Omicron) variants. Mechanistically, KA was shown to impair the post-entry steps of viral replication. In a subgenomic replicon system, we observed a decrease in viral RNA synthesis in different cell lines. Using an infectious virus, a larger reduction in the release of SARS-CoV-2 virions was observed. We suggest that KA interacts with SARS-CoV-2 proteases through molecular docking.ConclusionIn conclusion, KA emerges as an inhibitor of SARS-CoV-2 proteases and, consequently, its replication cycle. It could be a good candidate for further investigation in clinical assays against SARS-CoV-2 infection.
format Article
id doaj-art-111ad3122b7240acbcd4387128f12bbc
institution OA Journals
issn 1664-302X
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Microbiology
spelling doaj-art-111ad3122b7240acbcd4387128f12bbc2025-08-20T02:28:16ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2025-05-011610.3389/fmicb.2025.15409341540934Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitroIgor Andrade Santos0Igor Andrade Santos1Victoria Riquena Grosche2Victoria Riquena Grosche3Victoria Riquena Grosche4Natasha Marques Cassani5Natasha Marques Cassani6Rodrigo Cássio Sola Veneziani7Gustavo Lima Ribeiro8Jairo Kenupp Bastos9Nilson Nicolau-Junior10Andres Merits11Carlos Henrique Gomes Martins12Mark Harris13Ana Carolina Gomes Jardim14Ana Carolina Gomes Jardim15Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, BrazilFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomInstitute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, BrazilFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomInstitute of Biosciences, Humanities and Exact Sciences, São Paulo State University, São Jose do Rio Preto, BrazilInstitute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, BrazilFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomNucleus of Research in Sciences and Technology, University of Franca, Franca, BrazilNucleus of Research in Sciences and Technology, University of Franca, Franca, BrazilFaculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, BrazilInstitute of Biotechnology, Federal University of Uberlândia (UFU), Uberlândia, BrazilInstitute of Bioengineering, University of Tartu, Tartu, EstoniaInstitute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, BrazilFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomInstitute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, BrazilFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomIntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the coronavirus disease 2019 (COVID-19) pandemic, continues to pose global health challenges despite the availability of approved vaccines and antiviral drugs. The emergence of new variants of SARS-CoV-2 and ongoing post-COVID complications necessitate continuous exploration of effective treatments. Kaurenoic acid (KA) is a tetracyclic diterpenoid isolated from plants of the Copaifera genus and has been previously recognized for its anti-inflammatory, antibacterial, antifungal, and antitumor properties. However, there is a lack of knowledge about the in vitro effects of KA on viruses. Here, we evaluated its effect on SARS-CoV-2 replication for the first time.Methods and ResultsKA demonstrated a high selective index of 16.1 against SARS-CoV-2 and robust effectiveness against the B.1.617.2 (Delta) and BA.2 (Omicron) variants. Mechanistically, KA was shown to impair the post-entry steps of viral replication. In a subgenomic replicon system, we observed a decrease in viral RNA synthesis in different cell lines. Using an infectious virus, a larger reduction in the release of SARS-CoV-2 virions was observed. We suggest that KA interacts with SARS-CoV-2 proteases through molecular docking.ConclusionIn conclusion, KA emerges as an inhibitor of SARS-CoV-2 proteases and, consequently, its replication cycle. It could be a good candidate for further investigation in clinical assays against SARS-CoV-2 infection.https://www.frontiersin.org/articles/10.3389/fmicb.2025.1540934/fullantiviralCOVID-19natural compoundsSARS-CoV-2phytotherapeutics
spellingShingle Igor Andrade Santos
Igor Andrade Santos
Victoria Riquena Grosche
Victoria Riquena Grosche
Victoria Riquena Grosche
Natasha Marques Cassani
Natasha Marques Cassani
Rodrigo Cássio Sola Veneziani
Gustavo Lima Ribeiro
Jairo Kenupp Bastos
Nilson Nicolau-Junior
Andres Merits
Carlos Henrique Gomes Martins
Mark Harris
Ana Carolina Gomes Jardim
Ana Carolina Gomes Jardim
Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro
Frontiers in Microbiology
antiviral
COVID-19
natural compounds
SARS-CoV-2
phytotherapeutics
title Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro
title_full Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro
title_fullStr Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro
title_full_unstemmed Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro
title_short Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and release in vitro
title_sort kaurenoic acid is a potent inhibitor of sars cov 2 rna synthesis virion assembly and release in vitro
topic antiviral
COVID-19
natural compounds
SARS-CoV-2
phytotherapeutics
url https://www.frontiersin.org/articles/10.3389/fmicb.2025.1540934/full
work_keys_str_mv AT igorandradesantos kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT igorandradesantos kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT victoriariquenagrosche kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT victoriariquenagrosche kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT victoriariquenagrosche kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT natashamarquescassani kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT natashamarquescassani kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT rodrigocassiosolaveneziani kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT gustavolimaribeiro kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT jairokenuppbastos kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT nilsonnicolaujunior kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT andresmerits kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT carloshenriquegomesmartins kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT markharris kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT anacarolinagomesjardim kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro
AT anacarolinagomesjardim kaurenoicacidisapotentinhibitorofsarscov2rnasynthesisvirionassemblyandreleaseinvitro